Literature DB >> 4018098

The occurrence of two immunologically distinguishable beta-glucocerebrosidases in human spleen.

J M Aerts, W E Donker-Koopman, M K van der Vliet, L M Jonsson, E I Ginns, G J Murray, J A Barranger, J M Tager, A W Schram.   

Abstract

The beta-glucosidase activity in spleen from control subjects and patients with different clinical phenotypes of Gaucher's disease was characterized. The occurrence of a soluble non-specific beta-glucosidase with a neutral pH optimum and two membrane-associated beta-glucocerebrosidases with an acid pH optimum was demonstrated. The two beta-glucocerebrosidases can be distinguished on the basis of their ability to react with anti-(placental beta-glucocerebrosidase) antibodies bound to protein-A--Sepharose 4B beads. One of the splenic beta-glucocerebrosidases (form I) is precipitated by the immobilized antibodies and the other (form II) is not. The two forms also differ in binding affinity to concanavalin A, degree of stimulation of enzymic activity by taurocholate and isoelectric point. In contrast, the Km values of the two beta-glucocerebrosidases for natural and artificial substrates are similar and both are inhibited by conduritol B-epoxide. In spleen from three patients with type 1, one patient with type 2 and one patient with type 3 Gaucher's disease form I beta-glucocerebrosidase was found to be clearly deficient, whereas the activity of form II was 25-50% of that in control spleen. The non-specific, neutral beta-glucosidase was not deficient in these Gaucher spleens. The distinct biochemical and immunological properties of non-specific beta-glucosidase and the fact that normal levels of the enzyme are present in patients with Gaucher's disease indicate, in confirmation of previous reports, that non-specific beta-glucosidase is not related to beta-glucocerebrosidase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4018098     DOI: 10.1111/j.1432-1033.1985.tb09058.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  16 in total

1.  Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease.

Authors:  J M Aerts; W E Donker-Koopman; S Brul; S Van Weely; M C Sa Miranda; J A Barranger; J M Tager; A W Schram
Journal:  Biochem J       Date:  1990-07-01       Impact factor: 3.857

2.  Generation of polyclonal antibodies against recombinant human glucocerebrosidase produced in Escherichia coli.

Authors:  Juliana Branco Novo; Maria Leonor Sarno Oliveira; Geraldo Santana Magalhães; Ligia Morganti; Isaías Raw; Paulo Lee Ho
Journal:  Mol Biotechnol       Date:  2010-11       Impact factor: 2.695

3.  Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.

Authors:  S van Weely; M van den Berg; J A Barranger; M C Sa Miranda; J M Tager; J M Aerts
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

4.  Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.

Authors:  Amar Ghisaidoobe; Pieter Bikker; Arjan C J de Bruijn; Frithjof D Godschalk; Eva Rogaar; Marieke C Guijt; Peter Hagens; Jerre M Halma; Steven M Van't Hart; Stijn B Luitjens; Vincent H S van Rixel; Mark Wijzenbroek; Thor Zweegers; Wilma E Donker-Koopman; Anneke Strijland; Rolf Boot; Gijs van der Marel; Herman S Overkleeft; Johannes M F G Aerts; Richard J B H N van den Berg
Journal:  ACS Med Chem Lett       Date:  2010-12-02       Impact factor: 4.345

5.  Assessment of partially deoxygenated deoxynojirimycin derivatives as glucosylceramide synthase inhibitors.

Authors:  Richard J B H N van den Berg; Tom Wennekes; Amar Ghisaidoobe; Wilma E Donker-Koopman; Anneke Strijland; Rolf G Boot; Gijsbert A van der Marel; Johannes M F G Aerts; Herman S Overkleeft
Journal:  ACS Med Chem Lett       Date:  2011-04-07       Impact factor: 4.345

6.  Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow.

Authors:  J A Nolta; X J Yu; I Bahner; D B Kohn
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

7.  Characterization of glucocerebrosidase in Greek Gaucher disease patients: mutation analysis and biochemical studies.

Authors:  H Michelakakis; E Dimitriou; S Van Weely; R G Boot; I Mavridou; M Verhoek; J M Aerts
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

8.  Fluorescence assay of glucosylceramide glucosidase using NBD-cerebroside.

Authors:  A Abe; J A Shayman; N S Radin
Journal:  Lipids       Date:  1992-12       Impact factor: 1.880

Review 9.  Gaucher's disease and cancer: a sphingolipid perspective.

Authors:  Brian M Barth; Sriram S Shanmugavelandy; Diana M Tacelosky; Mark Kester; Samy A F Morad; Myles C Cabot
Journal:  Crit Rev Oncog       Date:  2013

10.  Glycomimetic affinity-enrichment proteomics identifies partners for a clinically-utilized iminosugar.

Authors:  Isa N Cruz; Conor S Barry; Holger B Kramer; C Celeste Chuang; Sarah Lloyd; Aarnoud C van der Spoel; Frances M Platt; Min Yang; Benjamin G Davis
Journal:  Chem Sci       Date:  2013-07-08       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.